<DOC>
	<DOCNO>NCT01975675</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy sofosbuvir ( SOF ) /ledipasvir ( LDV ) fixed-dose combination ( FDC ) tablet without ribavirin ( RBV ) treatment-naive treatment-experienced Japanese participant chronic genotype 1 HCV infection . Participants receive 12 week treatment continue assessment 24-week posttreatment follow-up period .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir/Ledipasvir ± Ribavirin Japanese Participants With Chronic Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Body weight ≥ 40 kg HCV RNA ≥ 10^5 IU/mL screen Current prior history clinicallysignificant illness ( HCV ) Pregnant nurse female male pregnant female partner Chronic liver disease nonHCV etiology Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>